FDA approves third over-the-counter opioid overdose nasal spray

The Food and Drug Administration (FDA) approved a third over-the-counter version of naloxone nasal spray Tuesday, in a move the agency said could save lives and reduce costs. 

The agency approved another Rextovy, a 4 milligram naloxone nasal spray for the emergency treatment of opioid overdose. FDA said consumers may directly buy it in pharmacies, convenience stores and online. 

Naloxone is a medicine that can help reduce opioid overdose deaths and when administered in time, usually within minutes of the first signs of an opioid overdose, can counter the overdose effects.

Rextovy is the third naloxone spray approved for use without a prescription, and FDA said having multiple approved formulations expands access and market availability, encourages competition that may reduce cost, and offers alternative sourcing........

© The Hill